Market closed
KemPharm/$ZVRA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About KemPharm
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Ticker
$ZVRA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
67
Website
KemPharm Metrics
BasicAdvanced
$431M
-
-$2.11
2.00
-
Price and volume
Market cap
$431M
Beta
2
52-week high
$9.40
52-week low
$4.20
Average daily volume
406K
Financial strength
Current ratio
2.884
Quick ratio
2.818
Long term debt to equity
85.118
Total debt to equity
85.892
Interest coverage (TTM)
-14.67%
Management effectiveness
Return on assets (TTM)
-32.80%
Return on equity (TTM)
-130.67%
Valuation
Price to revenue (TTM)
14.026
Price to book
6.16
Price to tangible book (TTM)
-77.55
Price to free cash flow (TTM)
-4.932
Growth
Revenue change (TTM)
47.85%
Earnings per share change (TTM)
255.12%
3-year revenue growth (CAGR)
-4.86%
3-year earnings per share growth (CAGR)
-10.61%
What the Analysts think about KemPharm
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for KemPharm stock.
KemPharm Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
KemPharm Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
KemPharm News
AllArticlesVideos
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™
GlobeNewsWire·2 weeks ago
Zevra Therapeutics to Participate at Upcoming Investor Conferences
GlobeNewsWire·2 weeks ago
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for KemPharm stock?
KemPharm (ZVRA) has a market cap of $431M as of February 15, 2025.
What is the P/E ratio for KemPharm stock?
The price to earnings (P/E) ratio for KemPharm (ZVRA) stock is 0 as of February 15, 2025.
Does KemPharm stock pay dividends?
No, KemPharm (ZVRA) stock does not pay dividends to its shareholders as of February 15, 2025.
When is the next KemPharm dividend payment date?
KemPharm (ZVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for KemPharm?
KemPharm (ZVRA) has a beta rating of 2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.